Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Early Clinical and Radiological Experience with a Ceramic Bone Graft Substitute in the Treatment of Benign and Borderline Bone Lesions.

Horstmann PF, Hettwer WH, Kaltoft NS, Petersen MM.

Sci Rep. 2018 Oct 18;8(1):15384. doi: 10.1038/s41598-018-33736-w.

2.

Natural Course of Local Bone Mineralization After Treatment of Benign or Borderline Bone Tumors and Cysts With a Composite Ceramic Bone Graft Substitute.

Horstmann PF, Hettwer WH, Petersen MM.

J Clin Densitom. 2018 Oct - Dec;21(4):472-479. doi: 10.1016/j.jocd.2017.12.004. Epub 2018 Mar 23.

PMID:
29661685
3.

Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions.

Kotrych D, Korecki S, Ziętek P, Kruk B, Kruk A, Wechmann M, Kamiński A, Kotrych K, Bohatyrewicz A.

Open Med (Wars). 2018 Oct 22;13:487-492. doi: 10.1515/med-2018-0072. eCollection 2018.

4.

Treatment of benign and borderline bone tumors with combined curettage and bone defect reconstruction.

Horstmann PF, Hettwer WH, Petersen MM.

J Orthop Surg (Hong Kong). 2018 May-Aug;26(3):2309499018774929. doi: 10.1177/2309499018774929.

PMID:
30428758
5.

Curettage of benign bone tumors and tumor like lesions: A retrospective analysis.

Kundu ZS, Gupta V, Sangwan SS, Rana P.

Indian J Orthop. 2013 May;47(3):295-301. doi: 10.4103/0019-5413.111507.

6.

[Treatment of juvenile bone cysts by curettage and filling of the cavity with BAS-0 bioactive glass-ceramic material].

Sponer P, Urban K.

Acta Chir Orthop Traumatol Cech. 2004;71(4):214-9. Czech.

PMID:
15456099
7.

[Filling of bone defects using biphasic macroporous calcium phosphate ceramic. Apropos of 23 cases].

Gouin F, Delécrin J, Passuti N, Touchais S, Poirier P, Bainvel JV.

Rev Chir Orthop Reparatrice Appar Mot. 1995;81(1):59-65. French.

PMID:
7569179
8.

Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects.

Saikia KC, Bhattacharya TD, Bhuyan SK, Talukdar DJ, Saikia SP, Jitesh P.

Indian J Orthop. 2008 Apr;42(2):169-72. doi: 10.4103/0019-5413.39588.

9.

Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors.

Friesenbichler J, Maurer-Ertl W, Bergovec M, Holzer LA, Ogris K, Leitner L, Leithner A.

Sci Rep. 2017 May 11;7(1):1736. doi: 10.1038/s41598-017-02048-w.

10.

Complete twelve month bone remodeling with a bi-phasic injectable bone substitute in benign bone tumors: a prospective pilot study.

Kaczmarczyk J, Sowinski P, Goch M, Katulska K.

BMC Musculoskelet Disord. 2015 Nov 26;16:369. doi: 10.1186/s12891-015-0828-3.

11.

The Use of Bone Graft Substitute in Hand Surgery: A Prospective Observational Study.

Liodaki E, Kraemer R, Mailaender P, Stang F.

Medicine (Baltimore). 2016 Jun;95(24):e3631. doi: 10.1097/MD.0000000000003631.

12.

Comparative performance of three ceramic bone graft substitutes.

Hing KA, Wilson LF, Buckland T.

Spine J. 2007 Jul-Aug;7(4):475-90. Epub 2007 Jan 24.

PMID:
17630146
13.

Does bone marrow affect the radiological outcome when added to biphasic ceramic graft in treatment of benign bone lesions?

El-Adl G, Ali AM.

Eur J Orthop Surg Traumatol. 2013 Jan;23(1):13-20. doi: 10.1007/s00590-012-0943-x. Epub 2012 Jan 22.

PMID:
23412403
14.

Composite ceramic bone graft substitute in the treatment of locally aggressive benign bone tumours.

Schindler OS, Cannon SR, Briggs TW, Blunn GW.

J Orthop Surg (Hong Kong). 2008 Apr;16(1):66-74.

PMID:
18453663
15.

Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone.

Gupta AK, Kumar P, Keshav K, Singh A.

Indian J Orthop. 2015 Nov-Dec;49(6):649-55. doi: 10.4103/0019-5413.168767.

16.

Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®.

Friesenbichler J, Maurer-Ertl W, Sadoghi P, Pirker-Fruehauf U, Bodo K, Leithner A.

Clin Orthop Relat Res. 2014 Mar;472(3):976-82.

17.

Biphasic bone substitute and fibrin sealant for treatment of benign bone tumours and tumour-like lesions.

Reppenhagen S, Reichert JC, Rackwitz L, Rudert M, Raab P, Daculsi G, Nöth U.

Int Orthop. 2012 Jan;36(1):139-48. doi: 10.1007/s00264-011-1282-y. Epub 2011 May 28.

18.

Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study.

Iundusi R, Gasbarra E, D'Arienzo M, Piccioli A, Tarantino U.

BMC Musculoskelet Disord. 2015 May 13;16:115. doi: 10.1186/s12891-015-0574-6.

19.

[Scintigraphic detection of osteoblast activity after implantation of BAS-0 bioactive glass-ceramic material into long bone defects].

Sponer P, Urban K, Urbanová E.

Acta Chir Orthop Traumatol Cech. 2006 Jun;73(3):176-82. Czech.

PMID:
16846563
20.

Treatment of benign bone lesions with an injectable calcium sulfate-based bone graft substitute.

Kelly CM, Wilkins RM.

Orthopedics. 2004 Jan;27(1 Suppl):s131-5.

PMID:
14763545

Supplemental Content

Support Center